UTSA Life Insurance Finance Class 15, October 15
Overview
The lecture examines why US healthcare spending is unusually high and argues that fragmented billing, fee-for-service incentives, weak price transparency, and overdiagnosis can generate costs without reliably improving outcomes. It compares US and international systems, reviews proposals such as Accountable Care Organizations, the No Surprises Act, Medicare drug-price negotiation, and value-based care, and emphasizes that better evidence on treatment effectiveness is essential for patients and policymakers.
Key takeaways
- Fee-for-service rewards treatment volume, while ACOs and value-based care attempt to reward lower costs and better outcomes; cited ACO savings are modest, around 1 to 2 percent of Medicare spending.
- Hospital pricing is difficult to compare: the lecture cites Atlanta-area colonoscopy prices ranging from $430 to $7,000 and notes that hospitals account for about one-third of US healthcare spending.
- The No Surprises Act took effect in 2022 and protects patients from certain out-of-network charges at in-network facilities by treating covered patient cost sharing as in-network.
- Overdiagnosis can lead to treatment for cancers that would never cause harm; estimates discussed suggest this may be true for 60 percent of prostate cancers and 20 to 30 percent of breast cancers.
- Outcome-based medicine requires reliable evidence about whether treatments improve health, yet the lecture characterizes roughly one-third of healthcare spending as waste that does not improve outcomes.
- Healthcare reform must balance efficiency and market power: concentrating complex procedures may improve provider experience, while hospital and PBM consolidation can also strengthen pricing power.
Chapters
- Healthcare challenges occur internationally, though US spending is especially high relative to the results it achieves.
- The UK’s National Health Service faces waiting lists and workforce departures, with healthcare workers further strained after COVID-19.
- Costa Rica can provide routine care but may leave families without support for uncommon or complex conditions.
- US hospitals are described as the most expensive part of the healthcare system, with an average patient-day cost compared to a $4,300 hotel room.
- The United States has about 5,700 hospitals, and many are nonprofit, challenging the claim that high costs arise simply from for-profit ownership.
- Fee-for-service pays doctors for each treatment, encouraging service volume rather than prevention, wellness, or keeping patients healthy.
- Affordable Care Act Accountable Care Organizations, or ACOs, aim to reward providers for reducing costs without lowering care quality.
- Studies cited in class estimate ACO savings at roughly 1 to 2 percent of Medicare spending, with debate over whether savings reflect better care or selection of healthier patients.
- Moving away from fee-for-service would require rewarding hospitals for preventing relapses and maintaining health, a shift the lecture connects to Michael Porter’s value-based care approach.
- Hospitals take in about $1.5 trillion, roughly one-third of US healthcare spending and three times the amount spent on medications, according to figures discussed.
- Since 2000, hospital prices have risen more than 250 percent, while about 70 percent of provider payments still follow traditional fee-for-service arrangements.
- A cited Atlanta-area colonoscopy sticker price ranged from $430 to $7,000, illustrating how hard it is to compare costs through complex billing.
- Hospital consolidation can raise prices through market power, but concentrating complex procedures may also improve provider experience and quality.
- CVS combines retail pharmacy, insurance through Aetna, pharmacy benefit management through Caremark, and investments in care delivery.
- Pharmacy benefit managers, or PBMs, act as intermediaries in prescription-drug coverage, and three major firms dominate the market.
- The Federal Trade Commission sued the largest PBMs in 2024 over insulin rebate practices; policy debates include rebate rules and whether savings reach patients.
- Hospital mergers can create both efficiencies and pricing power, while nonprofit status alone does not prevent hospitals from behaving commercially.
- A patient can visit an in-network hospital yet receive an out-of-network bill from an anesthesiologist, ambulance provider, or laboratory.
- The No Surprises Act, enacted in 2020 and effective in 2022, protects patients from certain out-of-network bills at in-network facilities and for air ambulance services.
- For covered services, patient cost sharing is treated as in-network, while the provider and health plan resolve the remaining payment between themselves.
- The law is a potential reform topic for further research, including whether early results show that it is reducing unexpected bills.
- One example involved a $17,000 urine-test bill after the insurer would have paid $101, demonstrating how an out-of-network charge can far exceed an insurer’s rate.
- A cited McAllen, Texas, example reported that 89 percent of patients received rebalance bills from doctors who did not accept their insurance, despite visiting in-network hospitals.
- When an insurer allows only $750 on a provider’s $3,000 charge, an out-of-network provider may still bill the patient for the difference.
- A patient treated for shoulder and back pain after a car accident was charged $44,914, including a $9,000 trauma-alert fee.
- A cited comparison found monthly spending on cancer patients in Washington was about $12,000, roughly twice the amount in British Columbia.
- Medicare’s large purchasing role makes drug-price negotiation a potential way to influence costs across the wider healthcare market.
- Administrative spending can reach 25 percent in the US, with fragmented systems requiring clinics to handle repeated forms, insurance paperwork, and payment follow-up.
- Patients often provide the same information across multiple paper forms, illustrating opportunities for digital intake and better-connected systems.
- US healthcare spending is higher than in Europe, but Americans also use more care and have higher incomes; life expectancy is about five years lower than Italy’s.
- The lecture notes that healthcare spending as a share of GDP has fallen back toward its 2008 level after rising sharply, even though total spending continues to grow.
- Healthcare and education are described as labor-intensive sectors where productivity gains are difficult, while paper forms and disconnected systems create inefficiencies.
- New treatments can increase spending by keeping people alive longer, while prevention, aspirin use, and generic drugs may help avoid some costly care.
- Overdiagnosis is not fraud or a false cancer diagnosis; it means detecting disease that may never harm the patient, while available evidence cannot always identify who needs treatment.
- For prostate cancer, the lecture gives an example in which 14 men undergo surgery for one life saved, while the others may face complications without benefiting.
- Active monitoring can avoid unnecessary treatment, but carries a risk that a cancer requiring intervention will progress before it is detected.
- The difficult question is who should decide whether to treat: the patient, the clinician, or a public payer such as the UK government.
- Outcomes-based medicine links payment and accountability to measurable patient results instead of the volume of services delivered.
- The lecture argues that clinicians and patients lack reliable data on whether many treatments work, leaving decisions about surgery and other care uncertain.
- Estimates discussed put waste at about one-third of healthcare spending, defined as spending that could be removed without changing health outcomes.
- The Affordable Care Act funded research into outcomes but, as described in class, restricted the use of cost-effectiveness findings in setting policy.
- The lecture describes concerns that PSA screening can trigger surgery even when the detected prostate cancer would never become life-threatening.
- A cited estimate links each life saved through prostate-cancer treatment to serious harms among other patients, including blood clots, heart attacks, and incontinence or impotence.
- New tests can identify abnormalities that lead to more procedures, even when the resulting treatment may be more harmful than the condition.
- Screening policies can focus on higher-risk groups and set stronger thresholds for biopsies and follow-up care.
- Estimates discussed suggest about 10 percent of lung tumors, 20 to 30 percent of breast cancers, and 60 percent of prostate cancers may never cause harm.
- A cancer diagnosis can trigger anxiety, additional testing, and treatment even when a tumor would remain stable and never spread.
- The National Cancer Institute recommendations described include reducing the frequency of some screening and concentrating tests on higher-risk groups.
- A cited estimate says overtesting, overdiagnosis, and overtreatment across conditions account for 10 to 30 percent of healthcare spending.
- A thyroid-cancer example compared an 185 percent increase in surgery with only a 7 percent decline in mortality, raising questions about the value of more operations.
- The key questions before surgery are the risks of dying without it, dying during surgery, and dying from cancer or treatment afterward.
- The lecturer’s thyroid treatment involved radioactive precautions, including isolation from visitors and restrictions on going near pregnant people.
- When clinicians cannot estimate those risks, patients cannot make well-informed choices; the class closes by emphasizing the need for treatment-outcome data.
Transcript excerpt
0:00 We've covered a lot of the template, so now we're we're just kind of hit and miss on a few special items. Some of them we talked about, but I didn't write anything down like um untying health insurance from the employer. Um so we'll see if we can find some good points on that. But we have covered quite a bit. I think we've covered the intro really really well. So I'm I'm in the list of articles on page 13. I don't want to spend a lot of time on NHS. The reason I'm talking about NHS in Canada and other countries is there's this belief that health care is only a problem in the United States, and that's just not true. It's a problem everywhere.
0:47 It's more serious in US when it comes to costs. There are some things the US is better than other countries are on on certain type of technologies, but the US, what it spends doesn't seem to get the benefit, but every country is struggling. You see in the UK waiting lists um and this is not that old of an article. Staff leading leaving the workforce. We saw a lot of that after COVID. We COVID has essentially just wore out the the health care industry. My sister-in-law is a doctor, and she's just she's moving to fewer hours. It just we just wore people out. Um >> [clears throat] >> so we're we're spending all this time, all this money, and yet we don't seem to have any any um
1:35 thing to prove for it. The UK, which people often say is the the the the best example of a government provided health care, is definitely struggling. How do you overhaul it? Um Essentially, right now everybody is treated the same.
This is the start of the transcript. Save this video free for the whole transcript, searchable and time-coded.
In this course
Related notes
Summary, takeaways, and chapters were generated by AI from the video's transcript and may contain errors. The video belongs to its creator, Professor Sweet.